Status of Small Dense LDL in Fasting and Nonfasting Lipidemia in Coronary Heart Disease

Similar documents
2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries

Metabolism and Atherogenic Properties of LDL

Katsuyuki Nakajima, PhD. Member of JCCLS International Committee

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017

REAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING

High density lipoprotein metabolism

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

Comparison of Fasting and Postprandial Lipid Profile in Patients of Coronary Heart Disease

Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD

Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease

Pathophysiology of Lipid Disorders

The Effects of Statin and Fibrate on Lowering Small Dense LDL- Cholesterol in Hyperlipidemic Patients with Type 2 Diabetes

N-3 Fatty Acids Non-HDL-Cand LDL-C Thomas Dayspring MD, FACP

JMSCR Vol 05 Issue 05 Page May 2017

Lipoprotein Particle Profile

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

ORIGINAL INVESTIGATION. Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease

Assessment of clinical profile of coronary artery disease in Indian Population

New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines

Chapter (5) Etiology of Low HDL- Cholesterol

A comparative study on the fasting and post prandial lipid levels as a cardiovascular risk factor in patients with type 2 diabetes mellitus

Study of relationship of serum Lipid Profile and etiological factors of Ischaemic Heart Diseases

JMSCR Vol 07 Issue 01 Page January 2019

13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah

BIOCHEMISTRY BLOOD - SERUM Result Range Units

Clinical Significance of Small Dense Low-Density Lipoprotein Cholesterol Levels Determined by the Simple Precipitation Method

Lipid/Lipoprotein Structure and Metabolism (Overview)

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers

Tracking a Killer Molecule

THE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES

LIPOPROTEINE ATEROGENE E ANTI-ATEROGENE ATEROGENE

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension

The Effects of Moderate Intensity Exercise on Lipoprotein-Lipid Profiles of Haramaya University Community

Nature Genetics: doi: /ng.3561

Measurement of Small Dense Low-density Lipoprotein Particles

HBA1C: PREDICTOR OF DYSLIPIDEMIA AND ATHEROGENICITY IN DIABETES MELLITUS

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?

Estimation of Plasma Small Dense LDL Cholesterol From Classic Lipid Measures

LIPOPROTEIN PROFILING

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Original Policy Date

Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins

Treatment of Atherosclerosis in 2007

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers. New and Old Biomarkers. Disclosures

The Metabolic Syndrome Prof. Jean-Pierre Després

ORIGINAL ARTICLE. Abstract. Introduction

EFFECT OF LYCOPENE IN TOMATO SOUP AND TOMATO JUICE ON THE LIPID PROFILE OF HYPERLIPIDEMIC SUBJECTS

Indian Journal of Basic & Applied Medical Research; December 2011: Issue-1, Vol.-1, P

Impact of Chronicity on Lipid Profile of Type 2 Diabetics

What Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives

The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS

Praveen Sharma*, Purvi Purohit and Rashmi Gupta 1

A Study to Show Postprandial Hypertriglyceridemia as a Risk Factor for Macrovascular Complications in Type 2 Diabetis Mellitus

EXECUTIVE SUMMARY OF THE MINOR RESEARCH PROJECT Submitted to UNIVERSITY GRANTS COMMISSION

Dyslipidemia Endothelial dysfunction Free radicals Immunologic

Status of LDL Oxidation and antioxidant potential of LDL in Type II Diabetes Mellitus

Role of Small Dense Low-Density Lipoprotein in Coronary Artery Disease Patients With Normal Plasma Cholesterol Levels. Small Dense KATAGIRI, MD, FJCC

Lipoproteins Metabolism

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Pattern of dyslipidemia and evaluation of non-hdl cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus

Leptin deficiency suppresses progression of atherosclerosis in apoe-deficient mice

Diabetic Dyslipidemia

Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease. Original Policy Date

ATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS

Gemfibrozil Improves Postprandial Hypertriglyceridemia in Patients with Isolated Low HDL

Plasma lipoproteins & atherosclerosis by. Prof.Dr. Maha M. Sallam

Zuhier Awan, MD, PhD, FRCPC

Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease

Cardiovascular Disease Prevention: Current Knowledge, Future Directions

Increasing HDL: the torcetrapib story

CHAPTER FORTY FIVE ENDOGENOUS LIPID TRANSPORT PATHWAY: VLDL AND IDL

Small Dense LDL Cholesterol is a Promising Biomarker for Secondary Prevention

Safety of Anacetrapib in Patients with or

Familial combined hyperlipidemia (FCH) was first described

ASSOCIATION BETWEEN BODY MASS INDEX, LIPID PEROXIDATION AND CORONARY LIPID RISK FACTORS IN HYPOTHYROID SUBJECTS

Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017

Prof. John Chapman, MD, PhD, DSc

Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine

Approach to Dyslipidemia among diabetic patients

Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University

SUPPLEMENTAL MATERIAL

Do Cholesterol Numbers Really Assess Cardiovascular Risk?


Lipid Lowering in Patients at High Risk for Cardiovascular Disease

Part 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD

Maintain Cholesterol

CETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia

Epidemiological studies have shown an association between

Non-High-Density lipoprotein cholesterol or Apolipoprotein B in the prediction of myocardial infarction

Transcription:

www.jmscr.igmpublication.org Impact Factor 1.1147 ISSN (e)-2347-176x Status of Small Dense LDL in Fasting and Nonfasting Lipidemia in Coronary Heart Disease Authors Pranshi Mishra¹, Neelima Singh²,Puneet Rastogi³ 1,2 Department of Biochemistry, G.R.Medical College, Gwalior ³Department of Medicine G.R.Medical College& J.A.group of Hospital, Gwalior Email-mishra.pranshi@gmail.com ABSTRACT LDL consists of heterogeneous spectrum of particles with highly variable atherogenic potential i.e. small dense LDL. The atherogenicity of sdldl is due to its high oxidizability, owing to low cholesterol and high PUFA and Apo B content. Since, small dense LDL whose half life is more than LDL-C in plasma, is coming up as new marker for CHD diagnosis. Hence, we aimed our study to know the status of sdldl along with other lipid parameters in nonfasting condition.the present study comprised of fifty clinically diagnosed cases of CHD admitted in ICU of J.A.group of hospital and fifty age and sex matched healthy individuals were considered as control subjects. Their fasting and nonfasting samples were analysed for lipid profile. There was a significant change in all the lipid parameters in nonfasting condition but small dense LDL varied minimally.on account of the small variation in the levels of sdldl in fasting and nonfasting state, compared to the other lipid parameters which show greater variability in both states, this small dense LDL can be a better marker for the diagnosis of coronary heart disease INTRODUCTION Life has its particle of risk--and in the bloodstream, some particles are riskier than others. Researchers reported that the littlest LDLs are the worst of all. By now, every sentient middle-aged adult has heard about "bad" and "good" cholesterol. But cholesterol is cholesterol; whether it's bad or good depends on how it's packaged. The low-density lipoproteins (LDLs) that transport cholesterol Pranshi Mishra et al IJMEIT Volume 2 Issue 6 June 2014 Page 1448

from the liver, where it's made, to other tissues cholesterol, triglycerides, LDL-C and low HDL can gum up artery walls, increasing a person's risk but many individuals with LDL-C apparently in for cardiovascular disease. normal range, may also suffer from CHD. Relative risk of all lipoproteins in CHD has been Sometimes patients are admitted in nonfasting extensively studied and the principle target for condition. The results of lipid profile particularly cardiovascular preventive strategies has been the TG, invariably changed or were incorrect under low density lipoprotein cholesterol. However LDL such circumstances. Since, small dense LDL consists of heterogeneous spectrum of particles whose half life is more than LDL-C in plasma, is with highly variable atherogenic potential i.e. coming up as new marker for CHD diagnosis. small dense LDL. The atherogenicity of sdldl is Hence, we aimed our study to know the status of due to its high oxidizability, owing to low sdldl along with other lipid parameters in cholesterol and high PUFA and Apo B content. nonfasting condition. Furthermore this molecule is depleted of vitamin E, which accounts for its susceptibility to MATERIAL AND METHODS oxidation [1]. In addition sdldl is cleared slowly The present study was conducted at department of by receptors as compared to large buoyant LDL Biochemistry and medicine department of and thus has a long residence period in plasma, J.A.Group of Hospitals, G.R. Medical College, allowing more time for them to be oxidized and Gwalior. The study included 50 normal healthy taken up by macrophages in extracellular spaces. persons of matched age and sex (group I) and 50 Low uptake by receptors has been attributed to diagnosed subjects of coronary heart disease decrease binding affinity to receptors due to admitted in the ICU of J.A. Hospital (group II). conformational change brought about in ApoB by Inclusion criteria: subjects who were diagnosed increase in TG content or decrease in size of with CHD and had symptoms like restlessness, LDL[2]. It is the TG content of LDL particles that chest pain and high blood pressure is associated with systemic inflammation. Exclusion criteria: subjects with any other Moreover, many individuals with LDL-C levels disease except CHD were excluded from the apparently within the normal range may also study. suffer from CHD [3]. Atherogenic lipoprotein The blood samples were drawn on the first day of phenotype is characterized by elevated levels of admission. 5ml of blood sample was obtained TG and sdldl particles and reduced HDL from each subject after overnight fasting and 5ml cholesterol (HDL C) [4]. It has been observed in non fasting condition under all aseptic that patients suffering from CHD when precautions for the analysis of lipid profile. investigated in fasting condition which is usually advised by clinician shows increased level of total Pranshi Mishra et al IJMEIT Volume 2 Issue 6 June 2014 Page 1449

ECG, Hb%, total and differential leucocyte count, height and weight were recorded at the time of admission in study proforma. Lipid profile was estimated by standard biochemical Kits (Erba) using BS 400 fully automated analyser (Mindray). Small dense LDL was calculated by using the regression equation by Srisawasdi et.al. [5]. This study was approved by institutional ethical committee & written consent was also obtained from the patients prior to study. Statistical analysis Paired sample t test was used to compare biochemical parameters within the groups. All analysis was done using Windows based SPSS statistical package (Version 16.0). RESULTS In CHD subjects and the control group subjects, overall status of the physiological parameters including age, height, weight, BMI (kg/m²) and hemoglobin showed no significant difference whereas systolic and diastolic blood pressure was significantly higher (p <.001) in CHD group (II) compared to the controls (I) (TABLE 1). TABLE 1: Characteristics Of The Subjects. (***P <.001) GROUPS AGE Ht. Wt. BMI Hb% SBP DBP GROUP I (n=50) Mean ± S.D 49.920 6.794 1.623.081 58.80 6.178 22.46 1.991 12.79 1.076 120.16 7.749 80.52 7.415 GROUP II (n=50) Mean ± S.D 53.76 11.032 1.6432.074 60.34 6.103 22.35 1.879 12.27 1.642 147.20 31.431*** 90.0 13.248*** There was a significant increase in lipid and lipoprotein profile in CHD subjects compared to control group except HDL. A significant decrease was observed for total cholesterol (p <.05) and LDL cholesterol in nonfasting state compared to fasting condition in both group I and group II. In contrast, there was significant increase in serum triglyceride and VLDL levels (p <.001) in nonfasting state in CHD patients as well as in the control group. There was no change in HDL C levels in fasting and nonfasting state in both the groups. Small dense LDL showed only very little variation in nonfasting condtion compared to fasting condition in both the groups (p <.05) (TABLE 2) Pranshi Mishra et al IJMEIT Volume 2 Issue 6 June 2014 Page 1450

TABLE 2: showing the status of fasting and nonfasting lipid profile in group I and group II.(*p<.05, **p<.01, ***p<.001) Group Parameter Fasting Non fasting Significance RANGE 155.56-225.40 154.12-224.43 TC Mean 183.66 180.56 ± SD 15.32 14.57** P<.01 RANGE 66.65-119.09 87.18-139.65 TG Mean ± SD 89.94 12.869 113.18 13.112*** RANGE 13.33-23.81 17.43-27.93 VLDL Mean 17.98 22.63 ± SD 2.573 2.622*** RANGE 44.04-55.76 44.13-55.23 HDL Mean 50.46 50.40 ± SD 2.615 2.525*** NS Group-I RANGE 89.21-140.73 83.16-132.32 (control ) LDL Mean 118.38 110.68 ± SD 10.445 11.821 RANGE 17.78-39.45 17.06-39.99 Sd LDL Mean 30.55 31.18 ± SD 4.530 4.934* p<.05 RANGE 195.32-308.72 192.28-303.12 TC Mean 279.34 275.73 ± SD 26.205 26.874** P<.01 RANGE 133.32-298.21 155.28-326.41 TG Mean 249.33 274.27 ± SD 40.886 42.499*** RANGE 25.19-54.19 26.06-54.02 VLDL Mean 49.86 54.85 ± SD 8.177 8.499*** RANGE 25.2-54.19 26.06-54.02 HDL Mean 39.41 39.31 ± SD 7.966 7.679(NS) NS Group-II RANGE 96.48-271.32 90.28-268.44 (CHD) Mean 197.03 189.66 LDL ± SD 47.445 48.197*** RANGE 28.93-104.26 26.73-106.43 Sd LDL Mean 70.64 71.72 P<.05 ± SD 19.046 19.721* DISCUSSION Elevated triglyceride levels have a substantial effect on lipoprotein metabolism, which explains much of the controversy about the role of serum triglycerides as a risk factor for CHD Atherosclerosis is described in some research studies as a postprandial phenomenon. Nonfasting lipoproteins are generally triglyceride rich, and if an individual has a predisposition to producing remnant particles or small, dense LDL-C and HDL-C particles, then clearance of these lipoprotein particles can be delayed as long as 12 Pranshi Mishra et al IJMEIT Volume 2 Issue 6 June 2014 Page 1451

hours or more [6]. In present study, the nonfasting to an elevated risk of CHD that is under genetic triglyceride levels were significantly high control and cannot be detected by simple compared to the fasting levels. This finding was measurement of fasting lipids. Thus, an increase similar to the findings of[7,8,9]. Levels of fasting of fasting and nonfasting TG levels might and nonfasting triglycerides are highly variable contribute to the high prevalence of small dense depending in part on the content of the last meal LDL particles in patients with CHD [11].In our and on the duration from the last meal taken. study the levels of small dense LDL were highly Nonfasting hypertriglyceridemia, reflecting an elevated in CHD subjects but there was a minimal elevated concentration of lipoprotein remnant variation in sdldl levels in nonfasting and particles, might change atherosclerotic lesion fasting state. This result was supported by the content and might show procoagulant, antifibrinolytic frinding of Sabaka et al [12]. On account of the and pro-inflammatory effects. The small variation in the levels of sdldl in fasting nonfasting VLDL levels showed a similar pattern and nonfasting state, compared to the other lipid to TG. In contrast to TG levels, serum LDL-c parameters which show greater variability in both levels were significantly low in nonfasting state states, this small dense LDL can be a better compared to fasting state. This result was marker for the diagnosis of coronary heart disease. supported by the findings of Shankar et al [8]. In fed state, with the influx of TG rich lipoproteins CONCLUSION from the intestines and subsequent lipolysis of Therefore it is concluded that another reason for triglycerides, there is transfer of cholesterol esters considering small dense LDL as a better predictor from HDL and LDL to these particles through the may be that, they are subfraction of LDL, formed action of CETP (Cholesterol ester transfer largely in response to high levels of TGs and are protein). This result in a decrease in LDL-C in the products of intravascular remodeling of TG nonfasting state compared to fasting state. High rich VLDL particle, so they can reflect the levels of VLDL participate in formation of sdldl combined effect of hypertriglyceridemia in this [10]. Nonfasting state modulates both metabolism disease. and composition of apo B-100 containing lipoprotein particles and it is probable that the REFERENCES intravascular cholesterol redistribution due to hyperlipidaemia modifies plasma lipoproteins [1]. Sharma SB, Garg S. Small dense LDL : Risk such that there is an increased generation of factor for coronary artery disease (CAD) and its potentially atherogenic TG rich lipoproteins and Therapeutic Modulation. Indian Journal of small dense LDL. Delayed lipid clearance from Biochemistry and Biophysics. 2012; 49: 77-85 body might reveal a state of fat intolerance linked Pranshi Mishra et al IJMEIT Volume 2 Issue 6 June 2014 Page 1452

[2]. Khan MS. Small Dense LDL: New Marker for Cardiovascular Risk Assessment and its Therapeutic Inflection. Biochem Anal Biochem 2012; 1 (6): 1-4 [3]. Arsenault BJ, Lemieux I, Despres JP, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM: Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. Eur Heart J 2007, 28:2770-7. [4]. Ai M, Otokozawa S, Asztalos B F, Ito Y, Nakajima K, White CC, Cupples L A, Wilson P W, Schaefer E. Small Dense LDL Cholesterol and Coronary Heart Disease:Results from the Framingham Offspring Study. Clinical Chemistry 2010;56 (6) :967 976 [5]. Srisawasdi P, Chaloeysup S, Teerajetgul Y, Pocathikorn A, Sukasem C, et al.estimation of Plasma Small Dense LDL Cholesterol From Classic Lipid Measures. Am J Clin Pathol 2011; 136: 20-29. and nonfatal coronary heart disease. Arch Intern Med. 2003; 163(9):1077-83 [8]. Shankar V, Kaur H, Dahiya K, Gupta MS. Comparison of Fasting and Postprandial Lipid Profile in Patients of Coronary Heart Disease. Bombay Hospital Journal 2008; 50: 1-5 [9]. Atar AI, Atar I, Aydınalp A, Ertan C, Bozbaş H, Özin B et al. Is there any relationship between coronary artery disease and postprandial triglyceride levels? Anadolu Kardiyol Derg 2011; 11: 201-6. [10]. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. Journal of Lipid Research 2002; 43: 1363-1376 [11]. Hirano T, Yasuki I, Koba S, Toyoda M, Ikejiri A, Saegusa H, Yamazaki J I, Yoshino G. Clinical Significance of Small Dense Low- Density Lipoprotein Cholesterol Levels determined by simple precipitation method. Arterioscler Thromb Vasc Biol 2004; 24:558-563 [6]. Patrick E. McBride. Triglycerides and Risk for Coronary Heart Disease.JAMA 2007; 298: 1-3 [7]. Eberly LE, Stamler J, Neaton JD. Relation of triglyceride levels, fasting and nonfasting, to fatal [12]. Sabaka P, Kruzliak P, Gaspar L, Caprnda M, Bendzala M, Balaz D. Postprandial changes of lipoprotein profile: effect of abdominal obesity. Lipids in Health and Disease 2013, 12:1-14 Pranshi Mishra et al IJMEIT Volume 2 Issue 6 June 2014 Page 1453